The FDA's complete response letter for Summit Therapeutics and Akeso's ivonescimab reveals more grievances than just an overall survival miss. Pfizer is licensing three in vivo autoimmune CAR-T programs from China's Starna Therapeutics. Chinese authorities have handed out penalties to individuals and organizations involved in a gene editing trial that led to a child's death. And more.
1. FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
FDA’s complete response letter for Summit’s ivonescimab cites China-heavy data beyond survival miss
The FDA has declined to approve Summit Therapeutics and Akeso’s PD-1xVEGF bispecific ivonescimab. The target indication was previously treated EGFR-mutated non-small cell lung cancer. While Summit cited a failed overall survival endpoint in a phase 3 trial as the reason for the rejection, the published complete response letter shows that the FDA flagged concerns over, among other things, China data contributing 93% of the progression-free survival events.
2. Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
Pfizer has penned a $2.6 billion deal for three preclinical in vivo CAR-T candidates from China’s Starna Therapeutics. While the $330 million-upfront deal currently only covers ex-China rights, Pfizer has the option to completely acquire the meds in the future. The three programs are focused on treating autoimmune diseases, with Pfizer also snaring rights to use Starna’s technology beyond immunology in oncology, plus the ability to license compounds from a separate collaboration.
Chinese authorities have fired two researchers involved in a gene editing study that led to the death of a child and a high-profile story by Science and Retraction Watch. The death sparked outside scrutiny over China’s investigator-initiated trial pathway. The penalties came after an investigation uncovered safety and ethical breaches in the scientists’ research conduct.
4. J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
Johnson & Johnson has agreed to buy Ollin Biosciences for $2.2 billion upfront and up to $1.125 billion in regulatory and commercial milestones. The announcement came just over a year after Ollin emerged with a VEGFxAng-2 bispecific antibody, a potential competitor to Roche’s blockbuster Vabysmo, licensed from Innovent Biologics.
5. AriBio’s oral Alzheimer’s drug meets monotherapy goal in phase 3 as Fosun weighs licensing option
AriBio’s PDE5 inhibitor mirodenafil posted mixed results in early Alzheimer’s disease. In a phase 3 trial, the drug outperformed placebo at slowing symptoms—but only in a subgroup of patients who were not on any background therapies such as an acetylcholinesterase inhibitor or memantine. Fosun Pharma has an option to potentially in-license the candidate.
Other News of Note:
6. Charles River pays $470M for 2 Frontage bioanalysis labs in Pennsylvania
7. Crown Biosciences stays put as $204M Adicon deal falls through
8. China’s national insurance covers 1st CAR-T, JW’s Carteyva after hefty discount (release)
9. CDMO Lotte inks commercial production deal as work on South Korean plant wraps
10. Europe's CHMP backs Baxfendy, gives Hansoh's Aumseqa another chance